Prospective Real-Life Multicenter Study of Tildrakizumab 200 mg for Moderate-to-Severe Psoriasis: Who Is the Ideal Patient?. (2024). Dermatology Practical & Conceptual, 14(4), e2024284. https://doi.org/10.5826/dpc.1404a284